Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 10;80(1):6. doi: 10.1007/s00018-022-04634-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022, corrected publication 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Validation of the oncogene addiction phosphorylation signature (OAPS) in NSCLC tissues. A Schematic workflow of the OAPS analysis by SRM in NSCLC tumor biopsies combining PDX models and ex vivo organotypic cultures. B Heat maps displaying OAPS changes in NSCLC patient tissues following 16 h of EGFR (gefitinib; upper left panel), MET (tepotinib; lower left panel), and ALK (crizotinib; right panel) inhibition. (LFC—log fold change in phosphorylation upon inhibition of addicting oncoprotein; cross—phosphopeptide not detected) C OAPS-derived score computed from phosphoproteomics in patient tissues (the score for up to three different inhibitors has been assessed for each patient). D Representative pictures of immunohistochemical staining (pEGFR—EGFR activation; Ki67—cell proliferation marker) of selected gefitinib-treated patient tissues (baseline—tissues stained prior start of the treatment, control—untreated tissues (OTCs) collected and stained at day 3, gefitinib—gefitinib-treated OTCs collected and stained at day 3 (48 h upon the start of EGFR inhibition)